| Literature DB >> 19079718 |
Alexandra Schneider1, Lucas Neas, Margaret C Herbst, Martin Case, Ronald W Williams, Wayne Cascio, Alan Hinderliter, Fernando Holguin, John B Buse, Kathleen Dungan, Maya Styner, Annette Peters, Robert B Devlin.
Abstract
BACKGROUND: Exposure to fine airborne particulate matter [< or =2.5 microm in aerodynamic diameter (PM(2.5))] has been associated with cardiovascular and hematologic effects, especially in older people with cardiovascular disease. Some epidemiologic studies suggest that adults with diabetes also may be a particularly susceptible population.Entities:
Keywords: air pollution; diabetes; endothelial dysfunction; environmental epidemiology; particulate matter
Mesh:
Substances:
Year: 2008 PMID: 19079718 PMCID: PMC2599761 DOI: 10.1289/ehp.11666
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Description of the study population characteristics: current nonsmoking subjects with type 2 diabetes mellitus.
| Characteristic | All subjects ( | Pulse waveform subjects ( |
|---|---|---|
| Age (years) | 61 ± 8 | 59 ± 6 |
| Male sex | 14 (64) | 7 (54) |
| Ethnicity | ||
| Caucasian | 15 (68) | 7 (54) |
| African American | 6 (27) | 6 (46) |
| Hispanic American | 1 (5) | 0 (0) |
| BMI (kg/m2) | 33 ± 7 | 34 ± 7 |
| ≥ 30 kg/m2 | 12 (55) | 7 (54) |
| Average systolic blood pressure ≥140 mmHg | 9 (41) | 6 (46) |
| Smoking | ||
| Never-smoker | 12 (55) | 8 (62) |
| Ex-smoker | 10 (45) | 5 (38) |
| Null polymorphism of | 10 (45) | 5 (38) |
| Valine-coding polymorphism of | 10 (45) | — |
| Aspartic acid–coding polymorphism H63D of | 4 (18) | — |
| Tyrosine-coding polymorphism C282Y of | 1 (5) | — |
| Serine-coding polymorphism P149S of | 4 (18) | — |
Values shown are mean ± SD or no. (%).
Four subjects declined permission for genetic testing.
Two subjects declined permission for genetic testing.
Two (9%) subjects were homozygous for the minor allele.
Sample size was too small for stratification on genotype.
No subjects were homozygous for the minor allele.
No subjects were homozygous for the minor allele.
One (5%) subject was homozygous for the minor allele.
Description of the study population clinical characteristics: current nonsmoking subjects with type 2 diabetes mellitus.
| Characteristic | All subjects ( | Pulse waveform subjects ( |
|---|---|---|
| Disease history | ||
| Type 2 diabetes mellitus | 22 (100) | 13 (100) |
| Time since diabetes diagnosis (years) | 6.4 ± 5.0 | 6.3 ± 6.0 |
| Hyperlipidemia | 19 (86) | 11 (85) |
| Hypertension | 19 (86) | 11 (85) |
| Past myocardial infarction | 0 (0) | 0 (0) |
| Coronary artery disease | 4 (18) | 1 (8) |
| Peripheral vascular disease | 3 (14) | 1 (8) |
| Cerebrovascular disease | 1 (5) | 0 (0) |
| Diabetic retinopathy | 1 (5) | 0 (0) |
| Diabetic nephropathy | 8 (36) | 7 (54) |
| Blood marker levels | ||
| HbA1c | 6.7 ± 0.9 | |
| ≥ 7% | 9 (41) | 6 (46) |
| Homocysteine | 12.9 ± 3.4 | |
| ≥12 μmol/L | 11 (50) | 7 (54) |
| Adiponectin | 4,727 ± 4,067 | |
| < 3,700 ng/mL | 11 (50) | 7 (54) |
| MPO | 9.8 ± 7.3 | |
| ≥7 ng/mL | 41 (51) | 24 (47) |
| Medication use | ||
| Sulfonylureas | 10 (45) | 6 (46) |
| Thiazolidinediones | 6 (27) | 2 (15) |
| Metformin | 14 (64) | 10 (77) |
| Statins | 12 (55) | 7 (54) |
| Aspirin | 14 (64) | 9 (69) |
| Beta-blockers | 9 (41) | 4 (31) |
| Angiotensin-converting enzyme inhibitors | 12 (55) | 8 (62) |
| Calcium blockers | 2 (9) | 1 (8) |
| Diuretics | 8 (36) | 6 (46) |
| Angiotension II receptor blocker | 3 (14) | 2 (15) |
| Estrogen | 2 (9) | 2 (15) |
Values shown are mean ± SD or no. (%).
Based on the screening urine ( > 30 μg albumin/mg creatinine) on spot collection.
HbA1c was measured only once, but homocysteine, adiponectin, and MPO were measured on all four visits. For the interaction analysis, we used the mean of the four measurements per subject for homocysteine and adiponectin. For MPO, we used all observations per patient because it showed high daily variation within subjects.
Data were missing from two subjects.
Data were missing from one subject.
Description of health parameters, PM2.5, and meteorology.
| Parameter | No. | Mean ± SD | Minimum | Maximum |
|---|---|---|---|---|
| Endothelial function parameters | ||||
| Brachial artery ultrasound | ||||
| Brachial artery diameter at baseline (mm) | 84 | 3.96 ± 0.65 | 2.91 | 5.98 |
| FMD (%) | 83 | 5.9 ± 3.9 | 0.4 | 16.3 |
| NTGMD (%) | 78 | 13.4 ± 7.4 | 3.8 | 32.1 |
| Pulse waveform | ||||
| LAEI (mL/mmHg × 10) | 51 | 16.5 ± 3.6 | 12.4 | 22.4 |
| SAEI (mL/mmHg × 100) | 47 | 4.2 ± 1.6 | 1.7 | 7.1 |
| SVR (dyne sec/cm5) | 51 | 1415.0 ± 244.0 | 959.6 | 1702.5 |
| Network PM2.5 | ||||
| PM2.5 (μg/m3) | 383 | 13.6 ± 7.0 | 2.0 | 38.9 |
| HSF rooftop meteorology | ||||
| Air temperature (°C) | 385 | 15.9 ± 8.5 | −6.5 | 31.5 |
| Relative humidity (%) | 385 | 62.5 ± 16.6 | 25.1 | 97.7 |
| Barometric pressure (hPa) | 386 | 1001.2 ± 6.5 | 981.4 | 1021.9 |
Brachial artery ultrasound values are the mean from the patient mean of four measurements from 22 subjects
Pulse waveform values are the mean from the patient mean of four measurements of 13 patients; one patient was excluded for the SAEI because of extremely high values.
Figure 1Patient visits, air temperature, and PM2.5 between 19 November 2004 and 9 December 2005. (A) Data points represent the week each of the 22 participants visited the HSF. (B) Daily 24-hr temperature averages (midnight to midnight) calculated from continuous 2-min data collected from the HSF rooftop. (C) Imputed 24-hr average PM2.5 concentrations (midnight to midnight) collected at the official network station.
Percent change of mean endothelial function and vascular compliance parameters per 10-μg/m3 increase in PM2.5 [estimate (95% CI)].
| PM2.5 days before clinical measurement | FMD | NTGMD | LAEI | SAEI | SVR |
|---|---|---|---|---|---|
| Lag 0 | −17.3 (−34.6 to 0.0)* | 2.5 (−9.0 to 13.9) | 0.4 (−4.2 to 5.0) | −3.0 (−13.0 to 7.0) | −1.6 (−3.7 to 0.4) |
| Lag 1 | −4.4 (−24.6 to 15.8) | −13.6 (−24.5 to −2.6)* | −0.3 (−6.0 to 5.4) | −17.0 (−27.5 to −6.4)** | 1.6 (−0.9 to 4.1) |
| Lag 2 | −18.6 (−44.8 to 7.6) | −10.2 (−23.5 to 3.0) | 2.5 (−4.3 to 9.4) | −9.7 (−23.5 to 4.2) | 3.5 (0.5 to 6.5)* |
| Lag 3 | 1.6 (−23.6 to 26.9) | −8.0 (−22.4 to 6.4) | −7.3 (−13.5 to −1.1)* | −15.1 (−29.3 to −0.9)* | 2.4 (−0.5 to 5.3) |
| Lag 4 | 18.4 (−3.5 to 40.3) | 3.6 (−7.9 to 15.0) | −2.3 (−8.0 to 3.3) | −2.1 (−14.0 to 9.7) | 3.2 (0.7 to 5.6)* |
| Five-day average | −19.4 (−62.6 to 23.8) | −19.4 (−44.3 to 5.5) | −4.6 (−15.3 to 6.1) | −25.4 (−45.4 to −5.3)* | 4.5 (−0.3 to 9.2) |
p < 0.05.
p < 0.01.
Figure 2Effect modification of FMD by markers representing diabetic disease control or medication use. The estimates are given as percent change of mean FMD level based on a 10-μg/m3 increment of PM2.5; error bars indicate 95% CIs. p-Values indicate the significance of the interaction term.
Figure 3Effect modification of FMD (A) and SAEI (B) by the GSTM1 genotype. The estimates are given as percent change of mean FMD level based on a 10-μg/m3 increment of PM2.5; error bars indicate 95% CIs. p-Values indicate the significance of the interaction term.